Analysis of the association between prospectively collected immune-related adverse events and survival in patients with solid tumor treated with immune-checkpoint blockers, taking into account immortal-time bias.
暂无分享,去创建一个
J. Soria | C. Robert | B. Besse | O. Lambotte | S. Champiat | A. Marabelle | C. Massard | J. Michot | M. Texier | M. Kfoury | S. Laghouati | A. Voisin | M. Najean | A. Lappara
[1] Zhuoli Zhang,et al. Association of Immune Related Adverse Events With Efficacy of Immune Checkpoint Inhibitors and Overall Survival in Cancers: A Systemic Review and Meta-analysis , 2021, Frontiers in Oncology.
[2] R. Fernandes,et al. Association between immune-related side effects and efficacy and benefit of immune checkpoint inhibitors - A systematic review and meta-analysis. , 2020, Cancer treatment reviews.
[3] S. Dalle,et al. Association between immune-related adverse events and long-term survival outcomes in patients treated with immune checkpoint inhibitors. , 2020, European journal of cancer.
[4] Fengchun Zhang,et al. Are immune-related adverse events associated with the efficacy of immune checkpoint inhibitors in patients with cancer? A systematic review and meta-analysis , 2020, BMC Medicine.
[5] R. Garje,et al. Review of Indications of FDA-Approved Immune Checkpoint Inhibitors per NCCN Guidelines with the Level of Evidence , 2020, Cancers.
[6] D. Schadendorf,et al. Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo , 2020, JAMA oncology.
[7] Douglas B. Johnson,et al. Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors , 2019, Journal of Immunotherapy for Cancer.
[8] S. Barni,et al. Immune-related Adverse Events and Survival in Solid Tumors Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis , 2019, Journal of immunotherapy.
[9] A. Alfranca,et al. Immune-related adverse events predict the therapeutic efficacy of anti-PD-1 antibodies in cancer patients. , 2019, European journal of cancer.
[10] R. Chiari,et al. Impact of immune-related adverse events on survival in patients with advanced non-small cell lung cancer treated with nivolumab: long-term outcomes from a multi-institutional analysis , 2018, Journal of Cancer Research and Clinical Oncology.
[11] J. Sugisaka,et al. Association of Immune-Related Adverse Events with Clinical Benefit in Patients with Advanced Non-Small-Cell Lung Cancer Treated with Nivolumab. , 2018, The oncologist.
[12] A. Diab,et al. The impact of immune checkpoint inhibitor-related adverse events and their immunosuppressive treatment on patients' outcomes , 2018, Journal of Immunotherapy and Precision Oncology.
[13] Kaoru Tanaka,et al. Association of Immune-Related Adverse Events With Nivolumab Efficacy in Non–Small-Cell Lung Cancer , 2017, JAMA oncology.
[14] Y. Koh,et al. Correlation between immune-related adverse events and efficacy in non-small cell lung cancer treated with nivolumab. , 2018, Lung cancer.
[15] M. Suarez‐Almazor,et al. Incidence of immune-related adverse events and its association with treatment outcomes: the MD Anderson Cancer Center experience , 2018, Investigational New Drugs.
[16] Tae Yong Kim,et al. Development of thyroid dysfunction is associated with clinical response to PD-1 blockade treatment in patients with advanced non-small cell lung cancer , 2018, Oncoimmunology.
[17] E. Plimack,et al. Immune-Related Adverse Events as a Biomarker in Non-Melanoma Patients Treated with Programmed Cell Death 1 Inhibitors. , 2017, The oncologist.
[18] C. Nam,et al. Statistical methods for elimination of guarantee-time bias in cohort studies: a simulation study , 2017, BMC Medical Research Methodology.
[19] D. Schadendorf,et al. Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] Hein Putter,et al. Understanding Landmarking and Its Relation with Time-Dependent Cox Regression , 2016, Statistics in Biosciences.
[21] P. Chanson,et al. Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.
[22] J. Soria,et al. Association of Vitiligo With Tumor Response in Patients With Metastatic Melanoma Treated With Pembrolizumab. , 2016, JAMA dermatology.
[23] G. Gibney,et al. Nivolumab in Resected and Unresectable Metastatic Melanoma: Characteristics of Immune-Related Adverse Events and Association with Outcomes , 2015, Clinical Cancer Research.
[24] A. Giobbie-Hurder,et al. Challenges of guarantee-time bias. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.